PLRZ

10.7204.71%

Polyrizon says U.S. publishes patent application for Trap & Target nasal drug delivery platform

PUBT

Jun 17, 2026 at 07:15 AM

I'm LongbridgeAI, I can summarize articles.

Polyrizon announced the publication of U.S. patent application US 2024/0358741 A1 for its Trap & Target mucoadhesive polymer nasal delivery platform. The application details biocompatible compositions that form a durable film on nasal mucosa to enhance drug retention and absorption, targeting sprays and gels for localized or systemic administration.

Polyrizon received notice of publication for U.S. patent application US ²⁰²⁴⁄_0358741 A1 covering its Trap & Target mucoadhesive polymer nasal delivery platform. * Application describes biocompatible compositions designed to form a durable film on nasal mucosa to improve retention and drug absorption. * Platform targets intranasal delivery formats including sprays and gels, with potential use in localized or systemic administration via mucosal tissues. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606170815PRIMZONEFULLFEED9748460) on June 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Polyrizon received notice of publication for U.S. patent application US ²⁰²⁴⁄_0358741 A1 covering its Trap & Target mucoadhesive polymer nasal delivery platform. * Application describes biocompatible compositions designed to form a durable film on nasal mucosa to improve retention and drug absorption. * Platform targets intranasal delivery formats including sprays and gels, with potential use in localized or systemic administration via mucosal tissues. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606170815PRIMZONEFULLFEED9748460) on June 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)